Click Here for a full summary of the webinar. The biopharma market has largely remained suppressed as we enter the final leg of what was a painful 2022. Private financings are down 80% and IPOs down 95% in volume since Q3 2021, while the performance of the XBI has dropped ~40% over the last 12 months. With the Federal Reserve continuing to raise interest rates and the looming impact of the Inflation Reduction Act, the macroeconomic headwinds at play bear uncertainty across the Biopharma sector. In this webinar, Locust Walk and other industry leaders exchanged their views on how to navigate this “narrow” depression and what companies can do to successfully make it to the other side.